Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating income | -$52.6M | -$103M | -$158M | -$177M |
| Net income | -$51.3M | -$89.6M | -$123M | -$141M |
| EPS (diluted) | -$5.51 | -$0.81 | -$0.78 | -$0.80 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$46.1M | -$79.5M | -$117M | -$222M |
| Capital expenditures | $155K | $2.17M | $1.29M | $3.61M |
| Free cash flow | -$46.3M | -$81.7M | -$118M | -$226M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $26.1M | $130M | $170M | $800M |
| Total assets | $97.8M | $482M | $903M | $1.58B |
| Total liabilities | $13.0M | $29.1M | $38.5M | $67.5M |
| Shareholders' equity | -$115M | $453M | $865M | $1.52B |
| Retained earnings | -$117M | -$207M | -$329M | -$470M |
| Shares (wtd avg diluted) | 9.58M | 110M | 158M | 178M |
Every figure is extracted from Structure Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.